Trial Profile
Observational Study; Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2014
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 28 Jan 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
- 19 Aug 2013 Planned end eate changed from 1 Mar 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 16 May 2013 Planned end date changed from 1 Nov 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.